Pooling sputum samples for the Xpert MTB/RIF assay: a practical screening strategy for highly infectious tuberculosis cases

Author:

Zeng Jianfeng,Huang Huan,Liu Xuhui,Huang Zhen,Liu Weijian,Liu Houming,Lu Shuihua

Abstract

AbstractThe Xpert MTB/RIF test (Xpert) can help in the accurate screening of tuberculosis, however, its widespread use is limited by its high cost and lack of accessibility. Pooling of sputum samples for testing is a strategy to cut expenses and enhance population coverage but may result in a decrease in detection sensitivity due to the dilution of Mycobacterium tuberculosis (Mtb) by sample mixing. We investigated how the mixing ratio affected the detection performance of Xpert. We used frozen sputum samples that had been kept after individual Xpert assays of the sputa from Mtb-confirmed TB patients and non-TB patients. Our results showed that the overall sensitivity of the Xpert pooling assay remained higher than 80% when the mixing ratio was between 1/2 and 1/8. When the mixing ratio was raised to 1/16, the positive detection rate fell to 69.0%. For patients with either a high sputum Mtb smear score ≥ 2+, a time-to-positive culture ≤ 10 days, or an Xpert test indicating a high or medium abundance of bacteria, the pooling assay positivity rates were 93.3%, 96.8%, and 100% respectively, even at a 1/16 mixing ratio. For participants with cavities and cough, the pooling assay positivity rates were 86.2% and 90.0% at a 1/8 ratio, higher than for those without these signs. Our results show that the Xpert pooled assay has a high overall sensitivity, especially for highly infectious patients. This pooling strategy with lower reagent and labor costs could support TB screening in communities with limited resources, thereby facilitating reductions in the community transmission and incidence of TB worldwide.

Funder

the Special Fund for Science and Technology Innovation of Guangdong

the Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties

Shenzhen Natural Science Foundation

the Shenzhen Clinical Research Center for Tuberculosis

the Special Fund Of Shenzhen Central-leading-local Scientific and Technological Foundation

Publisher

Springer Science and Business Media LLC

Reference9 articles.

1. WHO. Global tuberculosis report 2022. Geneva: World Health Organization. In.; 2022.

2. WHO. Global tuberculosis report 2021. Geneva: World Health Organization. In.; 2021.

3. WHO Guidelines Approved by the Guidelines Review Committee. In: WHO consolidated guidelines on tuberculosis: Module 2: screening– systematic screening for tuberculosis disease. edn. Geneva: World Health Organization© World Health Organization 2021.; 2021.

4. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, et al. Advances in Tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349–61.

5. Abdurrahman ST, Mbanaso O, Lawson L, Oladimeji O, Blakiston M, Obasanya J, Dacombe R, Adams ER, Emenyonu N, Sahu S, et al. Testing pooled sputum with Xpert MTB/RIF for diagnosis of Pulmonary Tuberculosis to increase affordability in low-income countries. J Clin Microbiol. 2015;53(8):2502–8.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3